<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520686</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-2.023</org_study_id>
    <nct_id>NCT03520686</nct_id>
  </id_info>
  <brief_title>QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.</brief_title>
  <official_title>QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, open-label, 3-cohort, randomized study to compare the safety and efficacy&#xD;
      of N-803 in combination with the current standard of care (experimental arms) versus standard&#xD;
      of care alone (control arms), as first-line treatment for subjects with stage 3 or 4 advanced&#xD;
      or metastatic NSCLC. Treatment will continue for up to 2 years, or until the patient&#xD;
      experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if&#xD;
      the investigator feels that it is no longer in the patient's best interest to continue&#xD;
      treatment. Patients will be followed for disease progression, post-therapies, and survival&#xD;
      through 24 months after the first dose of study drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by RECIST Version 1.1 based on BICR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by RECIST Version 1.1 based on BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by RECIST Version 1.1 based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by iRECIST based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by iRECIST based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by iRECIST based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>2 Months</time_frame>
    <description>Confirmed CR, PR, or SD lasting for at least 2 months by RECIST Version 1.1 based on BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life based on Patient Reported Outcomes Questionnaires</measure>
    <time_frame>24 Months</time_frame>
    <description>FACT-L</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent AEs and SAEs</measure>
    <time_frame>24 Months</time_frame>
    <description>Graded using the NCI CTCAE Version 5.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity profile of N-803 in combination with pembrolizumab.</measure>
    <time_frame>24 Months</time_frame>
    <description>Detection of anti-drug antibodies</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor molecular profiles and correlations with subject outcomes</measure>
    <time_frame>9 Weeks</time_frame>
    <description>Genomic sequencing of tumor cells from tissue</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1538</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A (Experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (Experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (Experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Pembrolizumab</intervention_name>
    <description>The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:&#xD;
Day 1, every 3 weeks:&#xD;
Pembrolizumab (200 mg intravenous infusion [IV])&#xD;
N-803 (15 μg/kg subcutaneously [SC])</description>
    <arm_group_label>Cohort A (Experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab</intervention_name>
    <description>The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:&#xD;
Induction (4 cycles):&#xD;
Day 1, every 3 weeks:&#xD;
Carboplatin (up to 900mg IV)&#xD;
Nab-paclitaxel (100mg/m² IV)&#xD;
Pembrolizumab (200mg IV)&#xD;
N-803 (15 μg/kg SC)&#xD;
Day 8:&#xD;
Nab-paclitaxel (100mg/m² IV)&#xD;
Day 15:&#xD;
Nab-paclitaxel (100mg/m² IV)&#xD;
Maintenance:&#xD;
Day 1, every 3 weeks:&#xD;
Pembrolizumab (200mg IV)&#xD;
N-803 (15 μg/kg SC)</description>
    <arm_group_label>Cohort B (Experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed</intervention_name>
    <description>The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:&#xD;
Induction (4 cycles):&#xD;
Day 1, every 3 weeks:&#xD;
Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)&#xD;
Pembrolizumab (200mg IV)&#xD;
Pemetrexed (500mg/m² IV)&#xD;
N-803 (15 μg/kg SC)&#xD;
Maintenance:&#xD;
Day 1, every 3 weeks:&#xD;
Pembrolizumab (200mg IV)&#xD;
N-803 (15 μg/kg SC)</description>
    <arm_group_label>Cohort C (Experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Drug: Pembrolizumab&#xD;
The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:&#xD;
Day 1, every 3 weeks:&#xD;
• Pembrolizumab (200 mg IV)</description>
    <arm_group_label>Cohort A (Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab</intervention_name>
    <description>The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:&#xD;
Induction (4 cycles):&#xD;
Day 1, every 3 weeks:&#xD;
Carboplatin (up to 900mg IV)&#xD;
Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)&#xD;
Pembrolizumab (200mg IV)&#xD;
Day 8:&#xD;
Nab-paclitaxel (100mg/m² IV) -if assigned to receive&#xD;
Day 15:&#xD;
Nab-paclitaxel (100mg/m² IV) -if assigned to receive&#xD;
Maintenance:&#xD;
Day 1, every 3 weeks:&#xD;
Pembrolizumab (200mg IV)</description>
    <arm_group_label>Cohort B (Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed</intervention_name>
    <description>The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:&#xD;
Induction (4 cycles):&#xD;
Day 1, every 3 weeks:&#xD;
Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)&#xD;
Pembrolizumab (200mg IV)&#xD;
Pemetrexed (500mg/m² IV)&#xD;
Maintenance:&#xD;
Day 1, every 3 weeks:&#xD;
Pembrolizumab (200mg IV)</description>
    <arm_group_label>Cohort C (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          3. Histologically-confirmed stage 3 or 4 NSCLC disease. Subjects with stage 3 disease&#xD;
             must not be candidates for treatment with surgical resection or chemoradiation.&#xD;
&#xD;
          4. Subjects must not have received prior systemic chemotherapy for advanced or metastatic&#xD;
             NSCLC. Previous neoadjuvant/adjuvant chemotherapy is allowed if completed ≥ 6 months&#xD;
             before diagnosis of metastatic disease. Subject's with newly-diagnosed stage 4 NSCLC&#xD;
             may have previously received systemic chemotherapy for stage 3 NSCLC.&#xD;
&#xD;
          5. For Cohort A only: NSCLC tumors must have PD-L1 expression (i.e. a TPS ≥1%) as&#xD;
             determined by an FDA-approved test.&#xD;
&#xD;
          6. The subject's tumor must not harbor an EGFR sensitizing (activating) mutation or ALK&#xD;
             translocation or targetable genomic aberration in BRAF, ROS1 or NTRK. EGFR sensitizing&#xD;
             mutations are those mutations that are amenable to treatment with tyrosine kinase&#xD;
             inhibitors including erlotinib, gefitinib, or afatinib. Investigators must be able to&#xD;
             produce the source documentation of the EGFR mutation, ALK translocation, and BRAF,&#xD;
             ROS1, and NTRK status. If any of the genomic changes described above are detected,&#xD;
             additional information regarding the mutation status of other molecules is not&#xD;
             required. If unable to test for these molecular changes, formalin fixed paraffin&#xD;
             embedded tumor tissue of any age should be submitted to a central laboratory&#xD;
             designated by the Sponsor for such testing. Subjects will not be randomized until the&#xD;
             EGFR , BRAFT, ROS1, and NTRK mutation status and ALK translocation status is available&#xD;
             in source documentation at the site.&#xD;
&#xD;
          7. ECOG performance status of 0 or 1.&#xD;
&#xD;
          8. Measurable tumor lesions according to RECIST 1.1.&#xD;
&#xD;
          9. Must be willing to release tumor biopsy specimen used for diagnosis of advanced or&#xD;
             metastatic NSCLC (if available) for exploratory tumor molecular profiling. If tumor&#xD;
             biopsy specimen is not available, subjects can still be enrolled.&#xD;
&#xD;
         10. Must be willing to provide blood samples prior to the start of treatment on this study&#xD;
             for exploratory tumor molecular profiling analysis.&#xD;
&#xD;
         11. Must be willing to provide a tumor biopsy specimen 9 weeks after the start of&#xD;
             treatment for exploratory analyses, if considered safe by the Investigator.&#xD;
&#xD;
         12. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol&#xD;
&#xD;
         13. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and&#xD;
             non-sterile male subjects must agree to use a condom for up to 4 months after&#xD;
             treatment. Effective contraception includes surgical sterilization (eg, vasectomy,&#xD;
             tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with&#xD;
             spermicide, intrauterine devices (IUDs), hormonal therapy, and abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          2. A history of prior malignancy with the following exceptions: cancer treated with&#xD;
             curative therapy with no disease recurrence for &gt;3 years, non-metastatic prostate&#xD;
             cancer controlled with hormonal therapy, or under observation; non-metastatic thyroid&#xD;
             cancer; basal or squamous cell carcinoma of the skin, superficial bladder cancer, or&#xD;
             in situ cervical cancer that has undergone successful definitive resection.&#xD;
&#xD;
          3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, or autoimmune disease associated with lymphoma).&#xD;
&#xD;
          4. History of organ transplant requiring immunosuppression; or history of pneumonitis or&#xD;
             interstitial lung disease requiring treatment with systemic steroids; or a history of&#xD;
             receiving systemic steroid therapy or any other immunosuppressive medication ≤ 3 days&#xD;
             prior to study initiation. Daily steroid replacement therapy (eg, prednisone or&#xD;
             hydrocortisone) and corticosteroid use to manage AEs are permitted.&#xD;
&#xD;
          5. Prior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of&#xD;
             study initiation.&#xD;
&#xD;
          6. Requirement for other forms of anticancer treatment while on trial, including&#xD;
             maintenance therapy, other radiation therapy, and/or surgery. Palliative radiation is&#xD;
             permitted.&#xD;
&#xD;
          7. Known CNS metastases or carcinomatous meningitis. Subjects with previously treated,&#xD;
             stable CNS metastases (no evidence of progression for ≥ 4 weeks, and resolution of&#xD;
             neurologic symptoms to baseline state) are permitted in this study.&#xD;
&#xD;
          8. History of receiving a live vaccine 30 days prior to study treatment.&#xD;
&#xD;
          9. History of human immunodeficiency virus (HIV), or known active hepatitis B or C&#xD;
             infection.&#xD;
&#xD;
         10. An active infection requiring systemic IV therapy.&#xD;
&#xD;
         11. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
         12. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. Absolute neutrophil count &lt; 1,500 cells/mm3.&#xD;
&#xD;
               2. Platelet count &lt; 100,000 cells/mm3.&#xD;
&#xD;
               3. Total bilirubin greater the upper limit of normal (ULN; unless the subject has&#xD;
                  documented Gilbert's syndrome).&#xD;
&#xD;
               4. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])&#xD;
                  &gt; 1.5 × ULN.&#xD;
&#xD;
               5. Alkaline phosphatase (ALP) levels &gt; 2.5 × ULN.&#xD;
&#xD;
               6. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L or creatinine clearance &lt; 40 mL/min&#xD;
                  (using the Cockcroft-Gault formula)&#xD;
&#xD;
         13. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with&#xD;
             uncontrolled hypertension should be medically managed on a stable regimen to control&#xD;
             hypertension prior to study entry.&#xD;
&#xD;
         14. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
         15. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         16. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         17. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 30 days prior to screening for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
         18. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         19. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         20. Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Garner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VP, Clinical Operations &amp; Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brooke Greenley, BS</last_name>
    <phone>919-810-0367</phone>
    <email>Brooke.Greenley@ImmunityBio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jayson Garmizo, MEng</last_name>
    <phone>310-912-2230</phone>
    <email>Jayson.Garmizo@ImmunityBio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Urological Institute - Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sellers, RN, BSN, CCRC</last_name>
      <phone>501-624-7700</phone>
      <email>Laura.Sellers@aoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Sheila Slone, RN</last_name>
      <phone>501-624-7700</phone>
      <email>Sheila.Slone@aoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Roy Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adventist Health Glendale</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>92106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Melendrez, CCRC</last_name>
      <phone>818-543-7574</phone>
      <email>MelendKM@ah.org</email>
    </contact>
    <investigator>
      <last_name>Mihran Shirinian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MemorialCare Health System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Alejo</last_name>
      <email>KGo@memorialcare.org</email>
    </contact>
    <investigator>
      <last_name>Amol Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adventist Health White Memorial</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raymundo Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atessa Kim</last_name>
      <phone>949-557-0290</phone>
      <email>atessa.kiani@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Chaitali Nangia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desert Hematology Oncology Medical Group</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Arrieta</last_name>
      <email>carolyndho@aol.com</email>
    </contact>
    <investigator>
      <last_name>Luke Dreisbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Quintana</last_name>
      <email>TQuintana@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Matthew Salzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health South Florida - Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Garcia</last_name>
      <phone>786-594-7565</phone>
      <email>GiovanniG@baptisthealth.net</email>
    </contact>
    <contact_backup>
      <last_name>Mari Vega, BA, CCRC</last_name>
      <phone>786-527-8866</phone>
      <email>MariVe@baptisthealth.net</email>
    </contact_backup>
    <investigator>
      <last_name>Federico Albrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network</name>
      <address>
        <city>Tinley Park</city>
        <state>Illinois</state>
        <zip>60487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health - Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karli Heasley</last_name>
      <phone>589-260-3196</phone>
      <email>Karli.Heasley@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Firas Badin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Dickerson</last_name>
      <phone>502-897-1166</phone>
      <email>Renee.Dickerson1@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Wangjian Zhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Doppel</last_name>
      <phone>313-576-9769</phone>
      <email>doppele@karmanos.com</email>
    </contact>
    <investigator>
      <last_name>Hirva Mamdani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Research Joplin</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esmeralda Carrillo</last_name>
      <email>Esmeralda.Carrillo@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Samir M Dalia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Cancer &amp; Hematology - Chub O'Reilly Cancer Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly McLaughlin</last_name>
      <phone>406-238-6290</phone>
      <email>Kelly.McLaughlin@sclhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather Duyck</last_name>
      <phone>406-238-6996</phone>
      <email>Heather.Ducyk@sclhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick W Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astera Cancer Care</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Percy Yeung</last_name>
      <email>percy.yeung@asterahealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Bruno Fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Jasek</last_name>
      <email>Amy_Jasek@URMC.Rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica E. Mackowiak</last_name>
      <email>Jessica_Ellis@URMC.Rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah Mulford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brooke Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roger Keresztes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Research Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Freeland, RN</last_name>
      <phone>405-752-3402</phone>
      <email>sheryl.freeland@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Carla Kurkjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LeHigh Valley</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Warner</last_name>
      <phone>713-334-4033</phone>
      <email>vwarner@gettysburgoncology.com</email>
    </contact>
    <investigator>
      <last_name>Satish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Leitner, MPH</last_name>
      <email>leitnera@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Godwin</last_name>
      <phone>843-792-8876</phone>
      <email>woodrufk@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Wrangle, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center/Bon Secours St. Francis Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Beckman</last_name>
      <email>melissa_beckman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert Siegel, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Clinical Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>MedoncResearch@avera.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Byers, BSN, RN</last_name>
      <phone>865-305-7136</phone>
      <email>ebyers@utuck.edu</email>
    </contact>
    <investigator>
      <last_name>Wahid Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Berryman</last_name>
      <email>courtney.berryman@bmhcc.org</email>
    </contact>
    <investigator>
      <last_name>Philip Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
      <email>Francisca.Fernandez@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Uyeki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawnna Bowers</last_name>
      <phone>817-359-9098</phone>
      <email>Shawnna.Bowers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Henrik Illum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Guerra</last_name>
      <email>lguerra@OncologyConsultants.com</email>
    </contact>
    <investigator>
      <last_name>Julio Peguero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Williams</last_name>
      <phone>804-893-8717</phone>
      <email>Mary_Williams7@bshsi.orgry</email>
    </contact>
    <investigator>
      <last_name>William J Irvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pembrolizumab</keyword>
  <keyword>N-803</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

